FEATURED ARTICLES
Validating A Better ALS Biomarker With Coya’s Fred Grossman
Coya Therapeutics President and CMO Fred Grossman, DO, FAPA discusses a potential new biomarker for ALS — 4-HNE, an oxidative stress biomarker — and how it could be more effective than the current standard, NfL.
-
![GettyImages-1329836000]( "How To Determine Country Feasibility For Cell And Gene Therapy Clinical Trials")
How To Determine Country Feasibility For Cell And Gene Therapy Clinical TrialsLearn how to choose the right location — globally — for your next cell and gene therapy clinical trial.
-
![GettyImages-2093406129]( "Shorter, Faster, Cheaper: Powerful New Data On Digital Endpoints")
Shorter, Faster, Cheaper: Powerful New Data On Digital EndpointsThe idea of leveraging novel, sensor-based measures to gather data for clinical trials is not new, but relevant evidence of their usefulness is. Here, DiMe experts discuss the impact of digital endpoints on trial success.
-
![David Lee Photo orig]( "Mission: Remission — Patient Need For Durable Treatment Informs J&J’s Ulcerative Colitis Trial")
Mission: Remission — Patient Need For Durable Treatment Informs J&J’s Ulcerative Colitis TrialJ&J Global Therapeutic Area Head, Immunology, David M. Lee, MD, Ph.D., talks about the progression from treating PsO and PsA to UC, the importance of integrating patient needs into the trial’s design, and the quest for a durable treatment that lends itself to total remission.
SERVICES & PRODUCTS
As a leading partner in ocular therapy, Altasciences is at the forefront of ophthalmic drug development. Our integrated CRO/CDMO solutions support programs from lead candidate selection to market. You will benefit from working with a single partner as your product advances through each phase of drug development—from prototype formulation through preclinical testing, to early phase clinical trials, and manufacturing. This could mean up to 40% in time savings.
Insights to guide your decision-making, from strategic planning to launch optimization and beyond.
Technology to meet the demands of today's clinical research and drug safety, ensuring innovation is at the forefront in clinical trial execution.
Data, tools, and guidance to identify and prioritize opportunities and optimize clinical trial planning.
Many biotechnology companies come to Australia to conduct early phase clinical trials and take advantage of straightforward regulatory streams and of the lucrative 43.5% R&D cash refund scheme. Biotechnology companies then often look at locations in Asia, such as South Korea, Thailand and China to tap into their huge treatment-naïve patient populations for their later phase clinical research.
Your therapy can make all the difference. Together, we’ll unlock its potential.